The rapid emergence of SARS-CoV-2 variants necessitates vaccines providing broad and durable protection. This study evaluates a self-amplifying RNA (saRNA) vaccine expressing a membrane-anchored receptor-binding domain (RBD-TM) of the SARS-CoV-2 spike protein. The saRNA RBD-TM vaccine, delivered in lipid nanoparticles (LNP), effectively induced T-cell and B-cell responses in non-human primates (NHPs) and protected hamsters and NHPs from SARS-CoV-2 challenge. Notably, RBD-specific antibodies against variants of concern (VOCs) persisted for at least 12 months in NHPs, suggesting this saRNA platform is a promising vaccine candidate for durable immunity against emerging SARS-CoV-2 strains.
Publisher
Nature Communications
Published On
May 19, 2023
Authors
Mai Komori, Takuto Nogimori, Amber L. Morey, Takashi Sekida, Keiko Ishimoto, Matthew R. Hassett, Yuji Matsuda, Hirotaka Ode, Tomokazu Tamura, Rigel Suzuki, Jeff Alexander, Yasutoshi Kido, Kenta Matsuda, Takasuke Fukuhara, Yasumasa Iwatani, Takuya Yamamoto, Jonathan F. Smith, Wataru Akahata
Tags
SARS-CoV-2
saRNA vaccine
immune response
RBD-TM
vaccine efficacy
variants of concern
durable immunity
Related Publications
Explore these studies to deepen your understanding of the subject.
